Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
25 hedge funds and large institutions have $1.22M invested in Statera Biopharma, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 8 closing their positions.
19% less funds holding
Funds holding: 31 → 25 (-6)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
21% less capital invested
Capital invested by funds: $1.55M → $1.22M (-$331K)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$263K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$21.9K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18K |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$3.22K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$917 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$18K |
| 2 |
AW
ACG Wealth
Atlanta,
Georgia
|
-$12K |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$11K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$8K |
| 5 |
VCAM
Van Cleef Asset Management
Beachwood,
Ohio
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VCAM
26
Van Cleef Asset Management
Beachwood,
Ohio
| – | -$5K | -500 | Closed |
|
27
Wells Fargo
San Francisco,
California
| – | -$917 | -100 | -67% |
|
28
BNP Paribas Financial Markets
Paris,
France
| – | -$393 | -41 | Closed |
|
29
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$275 | +30 | New |
|
STAB Hedge Fund Activity: Q3 2014 in Review
25 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2014, worth a combined $1.22M — down 21% from $1.55M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of STAB and 2 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Sabby Management, adding an estimated $263K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $18K sold.
- 25 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2014, down from 31 in Q2 2014.
- Funds reported $1.22M of Statera Biopharma, Inc. Common Stock stock for Q3 2014, down 21% quarter-over-quarter.
- 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2014 and 8 closed out, a net change of -6 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2014 was Sabby Management, an estimated $263K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q3 2014 was Renaissance Technologies, an estimated $18K sold.
Based on aggregated 13F filings for Q3 2014.